News | Brachytherapy Systems, Women's Healthcare | January 07, 2019

Prospective trial shows that intraoperative radiation therapy (IORT) is a clinically effective, faster and easier alternative to whole breast radiation therapy following breast-conserving surgery for selected low-risk patients at a median follow-up of 36 months

Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers

January 7, 2019 — Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent Electronic Brachytherapy (eBx) System were comparable to those seen in the TARGIT-A and ELIOT trials, according to new results. The results, published in the Annals of Surgical Oncology,1 came from a long-term study conducted at Hoag Memorial Hospital Presbyterian in Newport Beach, Calif.

The prospective study was led by Melvin J. Silverstein, M.D., medical director of the Hoag Breast Center, Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery at Hoag, and clinical professor of surgery at the Keck School of Medicine in Los Angeles. Hoag is a nonprofit, regional healthcare delivery network in Orange County, Calif., that treats more than 30,000 inpatients and 425,000 outpatients annually. The Hoag IORT series is currently the largest single-facility IORT series with the Xoft System in the United States. Researchers from Hoag have also published three additional studies on IORT with the Xoft System in peer-reviewed journals since 2016.

“On average, IORT can reduce 30 days of treatment to less than 30 minutes. The benefits are obvious,” said Silverstein. “Eliminating weeks of radiation therapy reduces emotional stress and allows patients to quickly return to their normal life. The results of this study have important implications for breast cancer patients around the world considering their treatment options.”

The study reviewed results of 1,000 early-stage breast cancers in 984 patients enrolled in a prospective trial from June 2010 to August 2017. Patients included individuals 40 years of age and older, with lymph node-negative cancer and with favorable pathology. All tumors were treated with breast-conserving surgery and IORT using the Xoft System. With a median follow-up of 36 months, there have been 28 ipsilateral local recurrences, ten of which were ductal carcinoma in situ (DCIS) and 18 invasive. There have been four regional nodal recurrences and one distant recurrence. There have been no breast cancer-related deaths. The low recurrence and complication rates reported support the continued study of IORT in appropriately selected women with low-risk breast cancer.

IORT with the Xoft System uses a miniaturized X-ray source to deliver one precise, concentrated dose of radiation to a tumor site at the time of breast-conserving surgery (lumpectomy). The treatment can be completed in as little as 8 minutes, making it possible for appropriately selected patients to replace six to eight weeks of post-operative external beam radiation therapy (EBRT) with a single treatment. The Xoft System is cleared by the U.S. Food and Drug Administration (FDA), CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers.

For more information: www.icadmed.com

Reference

1. Silverstein M.J., Epstein M., Kim B., et al. Intraoperative Radiation Therapy (IORT): A Series of 1000 Tumors. Annals of Surgical Oncology, published online July 2, 2018. https://doi.org/10.1245/s10434-018-6614-3

Related Content

News | Ultrasound Women's Health

August 10, 2022 — TransMed7, LLC announced that the first clinical cases of the final commercial production version of ...

Time August 10, 2022
arrow
News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
arrow
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
arrow
News | Breast Imaging

July 28, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), for patients with multiple architectural ...

Time July 28, 2022
arrow
News | Mammography

July 28, 2022 — The National Comprehensive Cancer Network (NCCN) has published new NCCN Guidelines for Patients: Breast ...

Time July 28, 2022
arrow
News | Nuclear Imaging

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing ...

Time July 27, 2022
arrow
Subscribe Now